Compare RSF & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RSF | ELOX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 52.5M |
| IPO Year | 2015 | 2013 |
| Metric | RSF | ELOX |
|---|---|---|
| Price | $14.06 | $11.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 6.3K | ★ 18.8K |
| Earning Date | 01-01-0001 | 11-16-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.04 | $10.00 |
| 52 Week High | $15.07 | $23.40 |
| Indicator | RSF | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 43.67 |
| Support Level | N/A | $12.47 |
| Resistance Level | $14.70 | $14.65 |
| Average True Range (ATR) | 0.10 | 1.00 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 17.65 | 48.37 |
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.